Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
CHIMERIX INC (CMRX)
|
Add to portfolio |
|
|
|
| Price: |
$6.80
| | Metrics |
| OS: |
88.6
|
M
| |
|
|
| Market cap: |
$602
|
M
| |
|
|
|
Net cash:
|
|
| |
|
|
|
EV:
|
$602
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 33.8 | 2.0 | 5.4 | 12.5 | 7.2 | 4.5 | 5.7 | 10.8 |
| Revenue growth | 1609.1% | -63.2% | -57.1% | 73.5% | 60.6% | -21.2% | -47.0% | 166.4% |
| Cost of goods sold | 0.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 33.4 | 2.0 | 5.4 | 12.5 | 7.2 | 4.5 | 5.7 | 10.8 |
| Gross margin | 98.7% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Selling, general and administrative | | | | | | | | |
| Research and development | 71.6 | 73.8 | 36.2 | 42.3 | 55.2 | 49.4 | 58.6 | 97.7 |
| General and administrative | 22.1 | 18.7 | 13.7 | 21.2 | 23.6 | 27.1 | 25.0 | 31.3 |
| EBIT | 169.3 | -90.5 | -44.5 | -50.9 | -71.6 | -72.1 | -78.0 | -118.3 |
| EBIT margin | 500.5% | -4573.5% | -828.7% | -406.9% | -992.3% | -1604.4% | -1367.1% | -1098.8% |
| Pre-tax income | 172.2 | -173.2 | -43.5 | -112.6 | -69.5 | -71.0 | -76.4 | -117.4 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | 172.2 | -173.2 | -43.5 | -112.6 | -69.5 | -71.0 | -76.4 | -117.4 |
| Net margin | 509.0% | -8753.7% | -810.2% | -899.2% | -962.8% | -1579.5% | -1339.7% | -1090.6% |
| |
| Diluted EPS | $1.94 | ($2.04) | ($0.70) | ($2.03) | ($1.43) | ($1.51) | ($1.65) | ($2.67) |
| Shares outstanding (diluted) | 88.8 | 84.9 | 62.2 | 55.5 | 48.6 | 47.0 | 46.3 | 43.9 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|